Search results: (10000)
News Efficacy of Conventional and Intensified Lifestyle Interventions in Individuals with Prediabetes According to Risk Level
Lifestyle changes can prevent the development of type 2 diabetes in individuals with prediabetes, but according to current findings, these measures fail for a significant portion of study participants. In the Diabetes Prevention Program (DPP) study, one in five patients in the lifestyle intervention group developed type 2 diabetes within 4 years. However, there are individuals with prediabetes who do not develop diabetes without lifestyle intervention even after 11 years of follow-up. This indicates the need to create more precisely stratified intervention strategies based on the identification of high-risk (HR) and low-risk (LR) individuals with prediabetes. This is precisely the focus of a recently published study by German authors.
News Safety of Tofacitinib in Ulcerative Colitis – Combined Results of 6 Studies
At the annual meeting of the American Gastroenterological Association (ACG) in October 2023 in Vancouver, Canada, the results of the final safety analysis of tofacitinib in the treatment of ulcerative colitis from a clinical trial program involving 1,157 patients with exposure duration to this therapy of up to 9.2 years were presented.
News Sport and Programmed Sports Therapy in Hemophiliacs
Sport and physical activity are increasingly becoming an integrated part of the treatment plan for hemophiliacs. It was not long ago that sports were almost forbidden for these patients. The possibilities for active movement were determined by the availability of effective treatment. It has also become clear that sport is not just sport but to some extent also part of the treatment – thanks to the care of experienced physiotherapists.
News The Benefit of Dabigatran Over Warfarin Is Greater in Patients with Atrial Fibrillation and Diabetes Than in Nondiabetics
As early as 2015, an analysis of the results of the RE-LY study in patients with atrial fibrillation showed that the reduction in absolute risk of embolic events with dabigatran compared to warfarin is greater in patients with diabetes than in those without diabetes.
News Safety of Dabigatran in Secondary Prevention of Venous Thromboembolism in Pediatric Patients
Low molecular weight heparin (LMWH) or warfarin (VKA – vitamin K antagonist) is typically used for the secondary prevention of venous thromboembolism. The DIVERSITY study extension examined the safety of dabigatran in this indication in pediatric patients.
News Need for Early Intervention in COPD − A Suitable Time for Mucolytic Treatment
Chronic Obstructive Pulmonary Disease (COPD) ranks third among the leading causes of morbidity and mortality worldwide, with more than 210 million people expected to be affected by 2030. While common, it is preventable and treatable. The mucolytic erdosteine has proven to be an effective helper in COPD therapy.
News Successful Long-Term Subcutaneous Prophylaxis of Hereditary Angioedema – Case Study
Hereditary angioedema (HAE), arising from a deficiency of C1 inhibitor (C1-INH), clinically manifests as swelling of the subcutaneous tissue and mucous membranes. The standard prophylactic therapy consists of intravenous (i.v.) substitution of C1-INH. We present a case study of successful long-term subcutaneous (s.c.) prophylaxis in a patient who had to discontinue i.v. prophylaxis.
News Participation in sports activities, frequency and severity of sports injuries in children with hemophilia
Children with hemophilia used to be discouraged from engaging in sports activities due to the potential increased risk of bleeding. The introduction of prophylaxis into routine practice has improved the possibility for children to participate in various sports activities. A study conducted by Dutch authors evaluated the involvement of boys with hemophilia in sports activities and their potential link with sports injuries and bleeding.
News Sport Therapy as Part of Hemophilia Management
A study by authors from the University of Wuppertal in Germany specifically examined the impact of a half-year programmed sport therapy on the subjective physical performance and quality of life of individuals with hemophilia.
News Can identifying alpha-1 antitrypsin deficiency before liver transplantation extend survival?
Alpha-1 antitrypsin deficiency (AATD) can manifest (among other things) as liver cirrhosis. The study presented below examined the survival of patients diagnosed with AATD before and after liver transplantation.
News Population Pharmacokinetic Model in Patients with von Willebrand Disease
Dutch authors presented a potential population pharmacokinetic model describing levels of von Willebrand factor and coagulation factor VIII during and after surgical procedures in patients with von Willebrand disease.
News How do Hemodialysis Patients Perceive the Coronavirus Pandemic? Survey Results
Hemodialysis patients are at higher risk of SARS-CoV-2 infection due to repeated visits to medical facilities. Additionally, these are often older and comorbid patients living in nursing homes. This study, presented below, examines how these patients perceived anti-epidemic measures during the first wave of the pandemic and how this extraordinary situation impacted their mental state.
News Lurasidone in the Treatment of Adolescent Schizophrenia: How Does It Compare with Other Atypical Antipsychotics?
A meta-analysis of 13 studies comparing lurasidone with other atypical antipsychotics in monotherapy for adolescent patients with schizophrenia evaluated the effectiveness of the treatment, the rate of weight gain, and the frequency of medication discontinuation for each modality.
News Shared Decision-Making on Kidney Function Replacement
Peritoneal dialysis (PD) is not a new development, but its significance is becoming increasingly recognized. Until recently, we may not have fully appreciated its value, but in light of the global threat posed by the current pandemic, its importance is starkly clear. PD is an accessible solution designed for home care and allows patients to avoid visits to healthcare facilities to some extent.
News Does SGLT2 Inhibitor Administration Benefit Diabetics with Low Cardiorenal Risk?
There is growing evidence of the cardiorenal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), which were developed as antihyperglycemic drugs for the treatment of type 2 diabetes. These antidiabetic medications are recommended for patients with heart or renal disease or at high risk of these complications. However, is it worthwhile to consider their use in diabetics as part of long-term primary cardiorenal prevention? Israeli authors sought the answer to this question.
News Hydroresponsive Dressings for Acute and Hard-to-Heal Wounds
A recently published review of clinical evidence from nearly three dozen studies demonstrates successful debridement and cleansing of various hard-to-heal wounds using HydroClean hydroresponsive dressing, with favorable healing outcomes.
News Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology
“Based on our experience so far, biosimilars represent an effective and safe alternative to original molecules. We are not afraid to use them anywhere in approved indications, and we are not afraid of switching either. Biosimilars are a significant step towards greater accessibility of hematooncological treatment for a wide group of patients,” states the head of the Hematology-Oncology Department of FN Plzeň, MUDr. Pavel Jindra, Ph.D., in our current interview.
News Impact of Tofacitinib on the Quality of Life of Patients with Ulcerative Colitis
Tofacitinib is an oral Janus kinase (JAK) inhibitor used in the treatment of certain rheumatic diseases and ulcerative colitis (UC). The work presented at this year's 18th congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen, Denmark, focused on its impact on the quality of life in terms of physical and mental functions in patients with UC.
News Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
With new treatment options for hemophilia A without inhibitors, the question of cost-effectiveness of different treatment approaches arises. The results of a model comparing replacement therapy and emicizumab in terms of cost-effectiveness were presented at a recently held ASH conference.
News Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice
Based on real-world data from the USA, a recently published study compared two recombinant human factor VIII (rFVIII) products with extended half-life (EHL) – efmoroctocog alfa and rurioctocog alfa pegol, in terms of dosing frequency, weekly consumption, and dose variability.
News Administration of Erdosteine after Severe COVID-19 in the Early Period after Discharging Patients from the Healthcare Facility
Erdosteine is a mucomodulatory drug used in the treatment of various acute and chronic respiratory diseases. According to available evidence, its mechanism of action is complex, encompassing not only a mucolytic effect but also antioxidant and antibacterial properties. Two clinical studies evaluated changes in respiratory distress parameters and quality of life in patients using this medication in the early period after discharge from a healthcare facility where they were hospitalized due to severe COVID-19.
News Consolidation therapy with brentuximab vedotin after autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma
At the 12th International Symposium on Hodgkin Lymphoma (ISHL), held in October 2022 in Cologne, results of a Czech study evaluating the efficacy and safety of consolidation therapy with brentuximab vedotin in patients after autologous stem cell transplantation were presented.
News Prevention and Treatment of Thromboembolism in the Elderly
Despite advances in the prevention and treatment of venous thromboembolism, morbidity and mortality associated with this condition remain high in certain risk groups. An international expert group focused on the elderly in its analysis published in the Thrombosis Journal.
News Modern View on Schizophrenia Therapy Through the Lens of Lurasidone
At the psychiatric symposium titled 'Chance for a Better Quality of Life with a Schizophrenia Diagnosis', which took place on October 18, 2021, in Prague, Professor of Psychiatry and Molecular Biology Christoph U. Correll from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell spoke. His lecture included insights on current approaches to schizophrenia therapy and key information on one of the newest antipsychotics - lurasidone.